A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer - First report from the Scandinavian Prostatic Cancer Group Study No. 6

被引:40
作者
Iversen, P
Tammela, TLJ
Vaage, S
Lukkarinen, O
Lodding, P
Bull-Njaa, T
Viitanen, J
Hoisaeter, P
Lundmo, P
Rasmussen, E
Johansson, JE
Persson, BE
Carroll, K
机构
[1] Univ Copenhagen, Rigshosp, Dept Urol, DK-2100 Copenhagen, Denmark
[2] Tampere Univ Hosp, Dept Urol, Tampere, Finland
[3] Cent Hosp Rogaland, Urol Sect, Rogaland, Norway
[4] Oulu Univ, Cent Hosp, Dept Urol, SF-90220 Oulu, Finland
[5] Sahlgrens Univ Hosp, Dept Urol, S-41345 Gothenburg, Sweden
[6] Aker Hosp, Dept Urol, Oslo, Norway
[7] N Karelian Cent Hosp, Joensuu, Finland
[8] Bergen Univ Hosp, Dept Urol, Bergen, Norway
[9] Univ Trondheim Hosp, Urol Sect, Trondheim, Norway
[10] Univ Copenhagen, Herlev Hosp, Dept Urol, Copenhagen, Denmark
[11] Orebro Univ Hosp, Dept Urol, Orebro, Sweden
[12] AstraZeneca, Sodertalje, Sweden
[13] AstraZeneca, Macclesfield, Cheshire, England
关键词
bicalutamide; early prostate cancer; standard care; disease progression; sexual function;
D O I
10.1016/S0302-2838(02)00311-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To assess the efficacy and tolerability of bicalutamide 150 mg ('Casodex'(1)) as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with early (T1b-T4, any N, M0) prostate cancer. Methods: This randomised, double-blind study was conducted in the Nordic countries as part of the 'Casodex' Early Prostate Cancer programme. Patients received bicalutamide 150 mg (n = 607) or placebo (n = 611) in addition to standard care. Results: More than 80% of patients had not received therapy of primary curative intent. Median follow-up in both groups was 3 years. Median exposure to study treatment in the bicalutamide and standard care alone groups was 2.5 and 2.3 years, respectively. Bicalutamide reduced the risk of objective disease progression by 57% compared with standard care alone (HR 0.43; 95% CI 0.34, 0.55; p < 0.0001). Survival data were immature (11.4% deaths) with no difference between the two treatment groups. Conclusions: Bicalutamide 150 mg as immediate therapy, either alone or as adjuvant to treatment of curative intent, significantly reduces the risk of disease progression in patients with early prostate cancer. The trial is ongoing to assess whether the reduction in risk of objective progression translates into an overall survival benefit. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:204 / 211
页数:8
相关论文
共 21 条
[11]  
Mettlin CJ, 1998, CANCER, V83, P1679, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1679::AID-CNCR24>3.0.CO
[12]  
2-Y
[13]  
POLLACK A, 1994, CANCER, V74, P670, DOI 10.1002/1097-0142(19940715)74:2<670::AID-CNCR2820740220>3.0.CO
[14]  
2-8
[15]   Natural history of progression after PSA elevation following radical prostatectomy [J].
Pound, CR ;
Partin, AW ;
Eisenberger, MA ;
Chan, DW ;
Pearson, JD ;
Walsh, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1591-1597
[16]   Long-term survival after radiotherapy alone: Radiation therapy oncology group prostate cancer trials [J].
Roach, M ;
Lu, JD ;
Pilepich, MV ;
Asbell, SO ;
Mohiuddin, M ;
Terry, R ;
Grignon, D .
JOURNAL OF UROLOGY, 1999, 161 (03) :864-868
[17]   The bicalutamide Early Prostate Cancer Program: Demography [J].
See, WA ;
McLeod, D ;
Iversen, P ;
Wirth, M .
UROLOGIC ONCOLOGY, 2001, 6 (02) :43-47
[18]   Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: First analysis of the early prostate cancer program [J].
See, WA ;
Wirth, MP ;
McLeod, DG ;
Iversen, P ;
Klimberg, I ;
Gleason, D ;
Chodak, G ;
Montie, J ;
Tyrrell, C ;
Wallace, DMA ;
Delaere, KPJ ;
Vaage, S ;
Tammela, TLJ ;
Lukkarinen, O ;
Persson, BE ;
Carroll, K ;
Kolvenbag, GJCM .
JOURNAL OF UROLOGY, 2002, 168 (02) :429-435
[19]   DEOXYRIBONUCLEIC-ACID PLOIDY OF CORE BIOPSIES AND METASTATIC LYMPH-NODES OF PROSTATE-CANCER PATIENTS - IMPACT ON TIME TO PROGRESSION [J].
VANDENOUDEN, D ;
TRIBUKAIT, B ;
BLOM, JHM ;
FOSSA, SD ;
KURTH, KH ;
TENKATE, FJW ;
HEIDEN, T ;
WANG, NN ;
SCHRODER, FH .
JOURNAL OF UROLOGY, 1993, 150 (02) :400-406
[20]   A structured debate: Immediate versus deferred androgen suppression in prostate cancer - Evidence for deferred treatment [J].
Walsh, PC ;
DeWeese, TL ;
Eisenberger, MA .
JOURNAL OF UROLOGY, 2001, 166 (02) :508-515